Overview

Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to assess the therapeutic activity and safety of the combination of Bendamustine and Rituximab in MALT lymphomas. Primary endpoint: - Event-free-survival (EFS) (failure or death from any cause) for all patients. Secondary endpoints: - Complete and partial remission rates for all patients - Response duration (time to relapse or progression) for responder patients - Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients - Overall survival for all patients - Acute and long-term toxicity

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Treatments:

Bendamustine Hydrochloride
Rituximab